Original Investigation

Effect of Intravitreal Bevacizumab Injection on Iridocorneal Angle Width

10.5152/imj.2013.50

  • Alper Ağca
  • Mustafa Doğan
  • Tuğrul Altan
  • Kadir Eltutar

Received Date: 19.05.2012 Accepted Date: 12.09.2012 İstanbul Med J 2013;14(3):188-190

Objective:

To evaluate the effect of intravitreal bevacizumab injection on iridocorneal angle width.

Methods:

Diabetic macular edema patients who l undergo intravitreal bevacizumab injection were included in the study if they had no iridocorneal angle pathologies on gonioscopy. Anterior segment optical coherence tomography was performed with RTVue (OptoVue Inc., Fremont, CA, USA) on 15 eyes of 15 patients to measure the angle opening distance at the Schwalbe’s line (SL-AOD) in the temporal quadrant before and just after the injection of 0.05 mL bevacizumab. The effect of the intravitreal injection on this parameter was evaluated.

Results:

10 patients were male and 5 were female. The mean age was: 58.4±5.5 years. All patients had Shaffer Grade 2 or wider angles in all the quadrants before the injection. Mean SL-AOD before the injection was 396.5±212.6 μ and mean SL-AOD after the injection was 364.3±215.4 μ. The difference was not statistically significant (p>0.05).

Conclusion:

Intravitreal injection of 0,05 mL bevacizumab has no detectable effect on anterior segment OCT images of iridocorneal angles in patients who have Shaffer Grade 2 or wider angles.

Keywords: Intravitreal injection, iridocorneal angle, optical coherence tomography, Schwalbe’s line, SL-AOD